Evaxion Biotech A/S announced that Niels Iversen Møller have mutually agreed that effective April 1, 2022, Dr. Møller will step down from his management roles with the Company as its Chief Business Officer and Interim Chief Financial Officer. Going forward, the Company and Dr. Møller have further agreed that he will continue to serve the Company in a non-management role as the Company's Vice President of Business. In Dr. Møller's place as Interim Chief Financial Officer, the Company has appointed Jesper Nyegaard Nissen, as Interim Chief Financial Officer, to be effective immediately upon the effective date of Dr. Møller's resignation.

Mr. Nissen is currently the Company's Chief Operating Officer and has more than 25 years of experience in the pharmaceutical industry across finance, investments as well as research and development.